Business Insider2d
LivaNova’s Promising OSPREY Study Results Propel Buy Rating Amid Strong OSA Market Potential
Anthony Petrone’s rating is based on several promising developments regarding LivaNova’s OSPREY study for treating obstructive sleep apnea (OSA). The company announced favorable 6-month results from ...
LivaNova’s OSPREY Trial Success Drives Buy Recommendation Amid Market Potential
Needham analyst Michael Matson has maintained their bullish stance on LIVN stock, giving a Buy rating on October 31. Michael Matson has given ...
Business Wire3d
LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints
LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation.
MassDevice3d
LivaNova nerve stim for sleep apnea meets primary study endpoints
LivaNova today announced that its OSPREY trial of nerve stimulation for treating sleep apnea met its primary endpoints.
Le Lézard3d
IAC Earnings Release and Letter to Shareholders Available on Company's Website
1 of 1' marketing platform, and our commitment to our... LivaNova PLC , a market-leading medical technology company, today announced that it met the primary endpoints for its OSPREY randomized ...